← Human Trials & Peer-Reviewed Studies
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
Plain-language guide to PMID 21645507 (2011): single-blind randomized controlled trial study of Exenatide in 2 patients, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 21645507
- Journal
- European journal of pharmacology
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Derosa G et al. (10 authors)
- DOI
- 10.1016/j.ejphar.2011.05.051
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin.
Why It Was Studied
The researchers evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA(1c), glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein.
Who Took Part
The study group was 2 patients.
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and single-blind.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind Exenatide study one party knew the assignments and the other did not.
A time span of 1 month appears in the methods.
What Was Measured
The researchers evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA(1c), glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein.
PubMed files the paper under topics including Biomarkers, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin and Inflammation.
What This Means in Plain Language
The paper is a randomized and single-blind study of Exenatide in 2 patients in people with insulin resistance, prediabetes & type 2 diabetes over 1 month.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2011 (European journal of pharmacology), a journal based in Netherlands.
More context: the Exenatide compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.